JP2016530323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530323A5 JP2016530323A5 JP2016542315A JP2016542315A JP2016530323A5 JP 2016530323 A5 JP2016530323 A5 JP 2016530323A5 JP 2016542315 A JP2016542315 A JP 2016542315A JP 2016542315 A JP2016542315 A JP 2016542315A JP 2016530323 A5 JP2016530323 A5 JP 2016530323A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- tumor
- antigen
- administered
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876509P | 2013-09-11 | 2013-09-11 | |
| US61/876,509 | 2013-09-11 | ||
| US201461971212P | 2014-03-27 | 2014-03-27 | |
| US61/971,212 | 2014-03-27 | ||
| US201461978401P | 2014-04-11 | 2014-04-11 | |
| US61/978,401 | 2014-04-11 | ||
| US201462003349P | 2014-05-27 | 2014-05-27 | |
| US62/003,349 | 2014-05-27 | ||
| PCT/EP2014/069425 WO2015036499A1 (en) | 2013-09-11 | 2014-09-11 | Anti-b7-h1 antibodies for treating tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081639A Division JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530323A JP2016530323A (ja) | 2016-09-29 |
| JP2016530323A5 true JP2016530323A5 (https=) | 2017-10-12 |
| JP6550053B2 JP6550053B2 (ja) | 2019-07-24 |
Family
ID=51570487
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542315A Active JP6550053B2 (ja) | 2013-09-11 | 2014-09-11 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2019081639A Pending JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2020152079A Active JP7119037B2 (ja) | 2013-09-11 | 2020-09-10 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2022021883A Active JP7342167B2 (ja) | 2013-09-11 | 2022-02-16 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2023139429A Pending JP2023166474A (ja) | 2013-09-11 | 2023-08-30 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081639A Pending JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2020152079A Active JP7119037B2 (ja) | 2013-09-11 | 2020-09-10 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2022021883A Active JP7342167B2 (ja) | 2013-09-11 | 2022-02-16 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2023139429A Pending JP2023166474A (ja) | 2013-09-11 | 2023-08-30 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10336823B2 (https=) |
| EP (2) | EP3656398A1 (https=) |
| JP (5) | JP6550053B2 (https=) |
| KR (5) | KR102661249B1 (https=) |
| CN (2) | CN112546217B (https=) |
| AU (3) | AU2014320343B2 (https=) |
| BR (1) | BR112016005303A2 (https=) |
| CA (1) | CA2923499A1 (https=) |
| DK (1) | DK3043816T3 (https=) |
| ES (1) | ES2749744T3 (https=) |
| HU (1) | HUE046674T2 (https=) |
| IL (5) | IL321966A (https=) |
| MX (1) | MX370818B (https=) |
| NZ (2) | NZ757060A (https=) |
| PL (1) | PL3043816T3 (https=) |
| RU (1) | RU2701327C2 (https=) |
| SA (1) | SA516370713B1 (https=) |
| TW (1) | TWI643633B (https=) |
| WO (1) | WO2015036499A1 (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015023120A2 (pt) | 2013-03-15 | 2017-11-21 | Genentech Inc | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado |
| WO2015036499A1 (en) | 2013-09-11 | 2015-03-19 | Medimmune Limited | Anti-b7-h1 antibodies for treating tumors |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| JP6666905B2 (ja) | 2014-05-29 | 2020-03-18 | スプリング バイオサイエンス コーポレーション | Ｐｄ−ｌ１抗体及びその使用 |
| EP3149043A1 (en) * | 2014-05-29 | 2017-04-05 | Medimmune Limited | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
| RU2715038C2 (ru) | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| US20170275347A1 (en) * | 2014-09-05 | 2017-09-28 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| ES2791950T3 (es) | 2015-02-03 | 2020-11-06 | Ventana Med Syst Inc | Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1) |
| RU2714233C2 (ru) | 2015-02-26 | 2020-02-13 | Мерк Патент Гмбх | Ингибиторы pd-1 / pd-l1 для лечения рака |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| RU2017136709A (ru) * | 2015-04-23 | 2019-05-23 | Медиммьюн Лимитед | Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr |
| ES2835866T5 (es) * | 2015-05-12 | 2024-12-02 | Hoffmann La Roche | Procedimientos terapéuticos y de diagnóstico para el cáncer |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| MY193229A (en) | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
| CA3025391A1 (en) * | 2016-05-26 | 2017-11-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for cancer treatment |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018003995A1 (ja) * | 2016-07-01 | 2018-01-04 | 国立大学法人東北大学 | 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法 |
| KR20190062515A (ko) | 2016-10-06 | 2019-06-05 | 화이자 인코포레이티드 | 암의 치료를 위한 아벨루맙의 투약 용법 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| MX2020001875A (es) | 2017-08-18 | 2020-07-29 | Tragara Pharmaceuticals Inc | Forma polimorfica de tg02. |
| JP7383620B2 (ja) * | 2018-01-31 | 2023-11-20 | セルジーン コーポレイション | 養子細胞療法およびチェックポイント阻害剤を使用する併用療法 |
| MX2020009550A (es) * | 2018-03-22 | 2020-11-11 | Keires Ag | Proteinas de union a antigeno antagonistas. |
| JP7574198B2 (ja) | 2019-01-18 | 2024-10-28 | ドラセン ファーマシューティカルズ インコーポレイテッド | Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法 |
| JP7582952B2 (ja) * | 2019-01-25 | 2024-11-13 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 腫瘍治療用の併用医薬組成物 |
| WO2020198435A1 (en) | 2019-03-26 | 2020-10-01 | The Regents Of The University Of Michigan | Small molecule degraders of stat3 |
| US12570679B2 (en) | 2019-03-29 | 2026-03-10 | Regents Of The University Of Michigan | STAT3 protein degraders |
| CN114269715A (zh) | 2019-06-12 | 2022-04-01 | 范德比尔特大学 | 作为氨基酸转运抑制剂的二苄基胺 |
| CA3141405A1 (en) | 2019-06-12 | 2020-12-17 | H. Charles Manning | Amino acid transport inhibitors and the uses thereof |
| KR20220026575A (ko) * | 2019-06-25 | 2022-03-04 | 시티 오브 호프 | Pdl1 양성 nk 세포 암 치료 |
| JP2022538284A (ja) | 2019-06-27 | 2022-09-01 | ザ ジョージ ワシントン ユニバーシティ， ア コングレッショナリー チャータード ノット－フォー－プロフィット コーポレイション | Ｈｄａｃ６活性化マクロファージ、その組成物および使用 |
| PH12021553233A1 (en) | 2019-07-16 | 2022-09-19 | Univ Michigan Regents | Imidazopyrimidines as eed inhibitors and the use thereof |
| AU2020336381A1 (en) | 2019-08-27 | 2022-03-03 | The Regents Of The University Of Michigan | Cereblon E3 ligase inhibitors |
| WO2021055756A1 (en) | 2019-09-19 | 2021-03-25 | The Regents Of The University Of Michigan | Spirocyclic androgen receptor protein degraders |
| WO2021057836A1 (en) * | 2019-09-25 | 2021-04-01 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| US12522623B2 (en) | 2020-03-26 | 2026-01-13 | Regents Of The University Of Michigan | Small molecule STAT protein degraders |
| WO2022011204A1 (en) | 2020-07-10 | 2022-01-13 | The Regents Of The University Of Michigan | Small molecule androgen receptor protein degraders |
| WO2022011205A1 (en) | 2020-07-10 | 2022-01-13 | The Regents Of The University Of Michigan | Androgen receptor protein degraders |
| WO2022072820A1 (en) | 2020-10-02 | 2022-04-07 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof |
| US20240190874A1 (en) | 2021-03-03 | 2024-06-13 | The Regents Of The University Of Michigan | Small molecule degraders of androgen receptor |
| WO2022187423A1 (en) | 2021-03-03 | 2022-09-09 | The Regents Of The University Of Michigan | Cereblon ligands |
| AU2022245277B8 (en) * | 2021-03-26 | 2025-08-07 | Astrazeneca Ab | Combination treatments for melanoma |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| WO2025151487A2 (en) | 2024-01-08 | 2025-07-17 | Regents Of The University Of Michigan | Small-molecule inhibitors of adar1 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2192884C2 (ru) * | 2000-11-09 | 2002-11-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Вакцина для стимуляции противоопухолевого иммунитета |
| US7794710B2 (en) * | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| US20100285039A1 (en) * | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| CN101693562A (zh) * | 2009-10-21 | 2010-04-14 | 山东大学 | 一种聚合氯化铁-聚环氧氯丙烷-二甲胺复合混凝剂 |
| PL2504364T3 (pl) * | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| KR101764096B1 (ko) * | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| WO2015036499A1 (en) * | 2013-09-11 | 2015-03-19 | Medimmune Limited | Anti-b7-h1 antibodies for treating tumors |
| PL3142751T3 (pl) * | 2014-05-13 | 2019-12-31 | Medimmune Limited | Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| US20170275347A1 (en) * | 2014-09-05 | 2017-09-28 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy |
| EP3220951A1 (en) * | 2014-11-17 | 2017-09-27 | MedImmune Limited | Therapeutic combinations and methods for treating neoplasia |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| WO2017189433A1 (en) * | 2016-04-25 | 2017-11-02 | Medimmune, Llc | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies |
| TW201741337A (zh) * | 2016-05-13 | 2017-12-01 | 麥迪紐有限責任公司 | ＣＤ４０Ｌ-Ｆｃ融合多肽及其使用方法 |
-
2014
- 2014-09-11 WO PCT/EP2014/069425 patent/WO2015036499A1/en not_active Ceased
- 2014-09-11 JP JP2016542315A patent/JP6550053B2/ja active Active
- 2014-09-11 NZ NZ757060A patent/NZ757060A/en unknown
- 2014-09-11 TW TW103131437A patent/TWI643633B/zh active
- 2014-09-11 CN CN202011433007.4A patent/CN112546217B/zh active Active
- 2014-09-11 IL IL321966A patent/IL321966A/en unknown
- 2014-09-11 NZ NZ718821A patent/NZ718821A/en unknown
- 2014-09-11 RU RU2016113341A patent/RU2701327C2/ru active
- 2014-09-11 PL PL14766962T patent/PL3043816T3/pl unknown
- 2014-09-11 KR KR1020227040760A patent/KR102661249B1/ko active Active
- 2014-09-11 KR KR1020257042956A patent/KR20260008188A/ko active Pending
- 2014-09-11 CA CA2923499A patent/CA2923499A1/en active Pending
- 2014-09-11 HU HUE14766962A patent/HUE046674T2/hu unknown
- 2014-09-11 KR KR1020247013414A patent/KR20240056664A/ko not_active Ceased
- 2014-09-11 ES ES14766962T patent/ES2749744T3/es active Active
- 2014-09-11 EP EP19191552.9A patent/EP3656398A1/en active Pending
- 2014-09-11 MX MX2016002826A patent/MX370818B/es active IP Right Grant
- 2014-09-11 KR KR1020167007277A patent/KR102329584B1/ko active Active
- 2014-09-11 BR BR112016005303A patent/BR112016005303A2/pt not_active Application Discontinuation
- 2014-09-11 DK DK14766962.6T patent/DK3043816T3/da active
- 2014-09-11 EP EP14766962.6A patent/EP3043816B1/en active Active
- 2014-09-11 IL IL313188A patent/IL313188B2/en unknown
- 2014-09-11 US US15/021,161 patent/US10336823B2/en active Active
- 2014-09-11 AU AU2014320343A patent/AU2014320343B2/en active Active
- 2014-09-11 CN CN201480049982.1A patent/CN105873606B/zh active Active
- 2014-09-11 KR KR1020217037457A patent/KR20210143932A/ko not_active Ceased
- 2014-09-11 IL IL292193A patent/IL292193B2/en unknown
-
2016
- 2016-03-03 IL IL244422A patent/IL244422B/en active IP Right Grant
- 2016-03-10 SA SA516370713A patent/SA516370713B1/ar unknown
-
2019
- 2019-04-23 JP JP2019081639A patent/JP2019163269A/ja active Pending
- 2019-05-21 US US16/418,488 patent/US10829557B2/en active Active
-
2020
- 2020-05-05 IL IL274462A patent/IL274462B/en unknown
- 2020-08-27 AU AU2020223728A patent/AU2020223728B2/en active Active
- 2020-09-10 JP JP2020152079A patent/JP7119037B2/ja active Active
- 2020-10-16 US US17/072,756 patent/US11827706B2/en active Active
-
2022
- 2022-02-16 JP JP2022021883A patent/JP7342167B2/ja active Active
-
2023
- 2023-08-30 JP JP2023139429A patent/JP2023166474A/ja active Pending
-
2024
- 2024-06-07 AU AU2024203898A patent/AU2024203898A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530323A5 (https=) | ||
| RU2016113341A (ru) | Антитела к b7-h1 для лечения опухолей | |
| JP2016520082A5 (https=) | ||
| Kordbacheh et al. | Current and emerging molecular therapies for head and neck squamous cell carcinoma | |
| JP2017537090A5 (https=) | ||
| JP2018512391A5 (https=) | ||
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| JP2022531408A5 (https=) | ||
| Chami et al. | Radiation and immune checkpoint inhibitors: combination therapy for treatment of hepatocellular carcinoma | |
| JP2022501332A5 (https=) | ||
| JP2008500964A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| US9415078B2 (en) | Method of treating desmocollin-3 expressing cancer with Mycobacterium w | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| JP2018501247A5 (https=) | ||
| Besse et al. | Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC) | |
| RU2812782C2 (ru) | Способ лечения острого миелоидного лейкоза | |
| RU2774721C2 (ru) | Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы | |
| RU2023133857A (ru) | Антитела к b7-h1 для лечения опухолей | |
| WO2023185720A1 (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| CN120605267A (zh) | 双氢青蒿素在制备结直肠癌转移药物方面的应用 | |
| CN119212695A (zh) | 施用用于诱导肿瘤相关抗原的苔藓虫素的方法 | |
| Salnikov et al. | 322 Efficacy of Amanitin Conjugated Chimeric Anti-EpCAM Monoclonal Antibody in Experimental Carcinomas | |
| Ciprotti et al. | 323 A Pilot Study of the Safety, Efficacy and Effects On Functional Imaging of the Combination of CG250 and Sunitinib in Patients (pts) with Advanced Renal Cell Carcinoma (RCC) | |
| RU2019129614A (ru) | Антитела к b7-h1 и к ctla-4 для лечения немелкоклеточного рака легкого |